Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide

被引:207
作者
Llinas, P
Le Du, MH
Gårdsvoll, H
Dano, K
Ploug, M
Gilquin, B
Stura, EA
Ménez, A
机构
[1] CEA, Dept Ingn & Etud Prot, Ctr Etud Saclay, F-91191 Gif Sur Yvette, France
[2] Rigshosp, Finsen Lab, DK-2100 Copenhagen, Denmark
关键词
cancer; structure; three-finger fold; tissue remodelling; uPAR;
D O I
10.1038/sj.emboj.7600635
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We report the crystal structure of a soluble form of human urokinase-type plasminogen activator receptor (uPAR/CD87), which is expressed at the invasive areas of the tumor-stromal microenvironment in many human cancers. The structure was solved at 2.7 angstrom in association with a competitive peptide inhibitor of the urokinase-type plasminogen activator (uPA)-uPAR interaction. uPAR is composed of three consecutive three-finger domains organized in an almost circular manner, which generates both a deep internal cavity where the peptide binds in a helical conformation, and a large external surface. This knowledge combined with the discovery of a convergent binding motif shared by the antagonist peptide and uPA allowed us to build a model of the human uPA-uPAR complex. This model reveals that the receptor-binding module of uPA engages the uPAR central cavity, thus leaving the external receptor surface accessible for other protein interactions (vitronectin and integrins). By this unique structural assembly, uPAR can orchestrate the fine interplay with the partners that are required to guide uPA-focalized proteolysis on the cell surface and control cell adhesion and migration.
引用
收藏
页码:1655 / 1663
页数:9
相关论文
共 60 条
[1]  
APPELLA E, 1987, J BIOL CHEM, V262, P4437
[2]   A region in domain II of the urokinase receptor required for urokinase binding [J].
Bdeir, K ;
Kuo, A ;
Mazar, A ;
Sachais, BS ;
Xiao, WZ ;
Gawlak, S ;
Harris, S ;
Higazi, A ;
Cines, DB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (37) :28532-28538
[3]   uPAR: A versatile signalling orchestrator [J].
Blasi, F ;
Carmeliet, P .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (12) :932-943
[4]   Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression [J].
Bolon, I ;
Zhou, HM ;
Charron, Y ;
Wohlwend, A ;
Vassalli, JD .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (06) :2299-2304
[5]  
BROOKS BR, 1988, PROTEINS THEORETICAL
[6]   Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions [J].
Cunningham, O ;
Andolfo, A ;
Santovito, ML ;
Iuzzolino, L ;
Blasi, F ;
Sidenius, N .
EMBO JOURNAL, 2003, 22 (22) :5994-6003
[7]   Maximum-likelihood heavy-atom parameter refinement for multiple isomorphous replacement and multiwavelength anomalous diffraction methods [J].
delaFortelle, E ;
Bricogne, G .
MACROMOLECULAR CRYSTALLOGRAPHY, PT A, 1997, 276 :472-494
[8]   Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? [J].
Deng, G ;
Curriden, SA ;
Wang, SJ ;
Rosenberg, S ;
Loskutoff, DJ .
JOURNAL OF CELL BIOLOGY, 1996, 134 (06) :1563-1571
[9]  
ELLIS V, 1989, J BIOL CHEM, V264, P2185
[10]   Differential binding of urokinase and peptide antagonists to the urokinase receptor: Evidence from characterization of the receptor in four primate species [J].
Engelholm, LH ;
Behrendt, N .
BIOLOGICAL CHEMISTRY, 2001, 382 (03) :435-442